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Esophageal cancer is the sixth most common cause of cancer‐related death, and 482 300 new cases were diagnosed during 2008.[1](#cas13308-bib-0001){ref-type="ref"}, [2](#cas13308-bib-0002){ref-type="ref"} Surgery is the cornerstone in treatment for esophageal cancer, with a median survival time of 13.6--19.3 months and 2‐year overall survival (OS) of 34%--45%.[3](#cas13308-bib-0003){ref-type="ref"}, [4](#cas13308-bib-0004){ref-type="ref"} However, fewer than 50% of newly diagnosed patients are suitable for curative resection.[5](#cas13308-bib-0005){ref-type="ref"}

The Radiation Therapy Oncology Group (RTOG) 85‐01 trial showed that 5‐fluorouracil plus cisplatin combined with radiotherapy significantly improved median survival and 5‐year OS compared with radiotherapy alone.[6](#cas13308-bib-0006){ref-type="ref"} Concurrent chemoradiotherapy (CRT) has become the standard treatment for patients with inoperable esophageal cancer, but the incidence of loco‐regional recurrence is over 50%.[7](#cas13308-bib-0007){ref-type="ref"}, [8](#cas13308-bib-0008){ref-type="ref"}, [9](#cas13308-bib-0009){ref-type="ref"}

Further attempts have been made to improve the therapeutic efficacy for esophageal cancer. Paclitaxel has notable activity in esophageal cancer and is a radiation sensitizer. The combination of paclitaxel with cisplatin seems to offer similar response rates and survival but less treatment‐related toxicity when concurrently administered with radiotherapy, compared with 5‐fluorouracil/cisplatin regimens.[10](#cas13308-bib-0010){ref-type="ref"}, [11](#cas13308-bib-0011){ref-type="ref"}

The esophagus contains an extensive submucosal lymphatic plexus; hence, dissemination to regional lymph nodes occurs early in esophageal cancer.[12](#cas13308-bib-0012){ref-type="ref"} The conventional clinical treatment volume (CTV) is adopted in radiotherapy without prophylactic elective nodal irradiation (ENI) to the draining lymphatics, which may lead to a high incidence of local‐regional recurrence. However, the benefit of ENI in chemoradiotherapy in preventing loco‐regional recurrence in esophageal cancer remains uncertain.[13](#cas13308-bib-0013){ref-type="ref"} A systematic review showed that ENI in chemoradiotherapy for esophageal cancer was feasible with acceptable toxicities.[14](#cas13308-bib-0014){ref-type="ref"} Several retrospective studies have reported that chemoradiotherapy with ENI significantly reduced the loco‐regional failure in patients with stage II/III esophageal cancer.[14](#cas13308-bib-0014){ref-type="ref"}, [15](#cas13308-bib-0015){ref-type="ref"} We postulated that the addition of ENI to chemoradiotherapy could improve prognosis in patients with inoperable esophageal cancer.

To date, the use of ENI in esophageal cancer is controversial due to a lack of prospective clinical trials. A rigorously designed retrospective study may provide evidence for establishing preferred treatment modality for patients with inoperable esophageal cancer. Therefore, we reviewed our institutional experience to compare the efficiency and safety of ENI with concurrent paclitaxel/cisplatin (TP) versus conventional‐field irradiation (CFI) with concurrent TP in patients with inoperable esophageal cancer.

Methods and Materials {#cas13308-sec-0002}
=====================

Patients {#cas13308-sec-0003}
--------

Eligible patients were required to have histologically confirmed esophageal cancer (either squamous cell carcinoma or adenocarcinoma) by biopsy. Additional inclusion criteria were as follows: age between 18 and 70 years; surgically or medically unresectable disease (stage T1--T4, N0/1, M0--1a according to the 2002 International Union Against Cancer TNM stage criteria) excluding patients with tracheesophageal fistula or complete esophageal obstruction; Eastern Cooperative Oncology Group performance status (ECOG PS) 0--2; and normal hemogram and adequate function of major organs (including cardiac, hepatic and renal function).

Ineligibility criteria included active uncontrolled infection; clinically significant cardiovascular disease; history of other malignancies; and previous treatment with radiotherapy, chemotherapy or immunotherapy.

The study was approved by the independent ethics committee of Wenzhou Medical University. The research protocol followed the Declaration of Helsinki. Informed consent was obtained from all patients before treatment initiation.

Pretreatment evaluation {#cas13308-sec-0004}
-----------------------

Pretreatment evaluation included barium swallowing, endoscopic ultrasound of the esophagus, and enhanced computed tomography (CT) of the neck, chest and abdomen. ^18^F‐fluorodeoxyglucose CT‐PET scan was optional.

Radiotherapy planning and target volume definition {#cas13308-sec-0005}
--------------------------------------------------

Radiotherapy (CFI and ENI) was delivered with megavoltage equipment (≥6 MV) using 3‐D conformal radiotherapy or intensity‐modulated radiation therapy, beginning on the first day of chemotherapy. The gross tumor volume (GTV) was defined as the primary tumor and any enlarged regional lymph nodes indicated by the transesophageal ultrasound, esophagram, CT scan and PET/CT (when available). The clinical target volume (CTV) consisted of CTV1 and CTV2. For patients receiving ENI, the initial clinical target volume (CTV1) included whole esophagus plus regional lymph nodes. According to the location of the tumor, the regional lymph nodes were prophylactic irradiated. For the cervical esophageal tumor, the level II/III lymph nodes in the neck, supraclavicular, paratracheal, posterior mediastinal, aortopulmonary, subcarinal, paraesophageal, pulmonary ligament, diaphragmatic and paracardial lymph nodes were included. For the upper and middle thoracic tumor, supraclavicular, paratracheal, posterior mediastinal, aortopulmonary, subcarinal, paraesophageal, pulmonary ligament, diaphragmatic, paracardial and left gastric lymph nodes were included. For the lower thoracic tumor, paratracheal, posterior mediastinal, aortopulmonary, subcarinal, paraesophageal, pulmonary ligament, diaphragmatic, paracardial, left gastric and celiac lymph nodes were included. For patients receiving CFI, CTV1 was defined as GTV plus superior--inferior 4‐cm margin and radial 1‐cm margin. After 40 Gy of radiotherapy, CTV2 (boost CTV) was defined as GTV plus the superior--inferior 2‐cm and radial 1‐cm margin. In patients receiving CFI, CTV1 was defined as GTV plus the superior--inferior 4‐cm margin and radial 1‐cm margin. After 40 Gy of radiotherapy, CTV2 (boost CTV) was defined as GTV plus the superior--inferior 2‐cm and radial 1‐cm margin. A total of 60 Gy of radiation doses was delivered over 30 fractions in 6 weeks. Initially, 40 Gy was given to CTV1, and a boost dose of 20 Gy was then delivered to CTV2. The maximum dose to the spinal cord was limited to 45 Gy and the lung V20 was less than 35%. Patients\' radiotherapy was postponed when grade 4 hematological toxicity or grade 3/4 toxicities related to radiation (esophagitis and gastrointestinal reactions) developed at the clinician\'s discretion. The radiation therapy resumed until the toxicity improved to grade 2 or less, with no reduction in prescribed radiation dose.

Chemotherapy regimen and dose modification {#cas13308-sec-0006}
------------------------------------------

All patients received chemotherapy comprising intravenous paclitaxel (135 mg/m^2^, day 1) and cisplatin (20 mg/m^2^, days 1--3) or oxaliplatin (130 mg/m^2^, day 2) every 4 weeks for two cycles. Doses used in the second cycle were adjusted according to toxicities in the first cycle.

A suspension of chemotherapy dosing was required if patients developed grade 3 leucocytopenia with fever or grade 4 leucocytopenia, and the chemotherapy restarted when the toxicity improved to grade 2 and with a 20% dose reduction of cisplatin and paclitaxel. Prophylaxis use of granulocyte colony‐stimulating factors was permitted according to physician\'s decisions. In addition, cisplatin was given at a 20% dose reduction to patients with a glomerular filtration rate (GFR) of less than 50 mL/min.

Response and toxicity assessment {#cas13308-sec-0007}
--------------------------------

Toxicity assessment was performed weekly during the treatment. Acute toxicity of the treatment was evaluated according to the Common Toxicity Criteria for Adverse Events Version 3.0 (CTCAE v3.0). Clinical response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 4--6 weeks after completion of the treatment regimen. Late toxicity was evaluated based on the RTOG/European Organization for Research and Treatment of Cancer (EORTC) criteria 6 months after the completion of the treatment regimen. Per‐protocol population in this study was defined as receiving at least one cycle of chemotherapy and a radiation dose of 60 Gy, or two cycles of chemotherapy and a radiation dose of more than 50 Gy.

Follow‐up {#cas13308-sec-0008}
---------

Follow‐up visits occurred every 3 months during the first 2 years, then every 6 months until 5 years and yearly thereafter. At each visit, a physical examination was performed, and a barium swallow, chest CT, and abdominal ultrasound were obtained. 18F‐fluorodeoxyglucose PET‐CT scan was optional. Additional tests were performed as clinically indicated.

Statistical analysis {#cas13308-sec-0009}
--------------------

The primary endpoint was overall survival (OS). The second endpoints included disease‐free survival (DFS), local recurrence‐free survival (LRFS), and treatment toxicity. All time‐related endpoints were measured from when treatment was initiated. We assessed the time‐to‐event endpoint using the Kaplan--Meier method and applied the log‐rank test for comparison. The χ^2^‐test and Student\'s *t*‐test were used to evaluate differences in groups\' characteristics and treatment toxicities. Independent prognostic factors were identified by multivariate analyses using the Cox proportional hazards model. All of the statistical analyses were performed using the SPSS 17.0 statistical software (SPSS, Chicago, IL, USA). A two‐sided *P*‐value \<0.05 was considered statistically significant.

Results {#cas13308-sec-0010}
=======

Patient characteristic {#cas13308-sec-0011}
----------------------

Between October 2000 and December 2005, a total of 89 patients (51 in the ENI group and 38 in the CFI group) with inoperable esophageal cancer were enrolled. There were no significant differences in baseline characteristics between the two groups (Table [1](#cas13308-tbl-0001){ref-type="table-wrap"}). The median age was 65 years (range, 47--75 years). The tumor histology was squamous cell cancer in 87 patients (97.8%). In the present study, 50.6% of the patients had stage III/IV cancer. The location of the primary tumors included cervical/upper/middle/lower thoracic portions, with the following distribution: 5/26/42/16 (5.6%/29.2%/47.2%/18.0%). After CRT, 62 patients (69.7%) achieved CR/PR with the following distribution in ENI/CFI groups: 37/25 (72.5%/65.8%).

###### 

Patient and tumor characteristics

  Characteristics                                ENI (*N* = 51)   CFI (*N* = 38)   *P*‐value           
  ---------------------------------------------- ---------------- ---------------- ----------- ------- -------
  Age(years)                                                                                           
  \<65                                           27               52.9             19          50.0    0.784
  ≥65                                            24               47.1             19          50.0    
  Gender                                                                                               
  Male                                           49               96.1             36          94.7    1.000
  Female                                         2                3.9              2           5.3     
  ECOG PS                                                                                              
  0--1                                           37               72.5             31          81.6    0.321
  2                                              14               27.5             7           18.4    
  Tumor Length (cm)                                                                                    
  \<5                                            6                11.8             8           21.1    0.301
  5--8                                           28               54.9             22          57.9    
  \>8                                            17               33.3             8           21.1    
  Pathology                                                                                            
  Squamous carcinoma                             49               96.1             38          100.0   
  Adenocarcinoma carcinoma                       1                2                0                   
  Adenosquamous carcinoma                        1                2                0                   
  Tumor differentiation                                                                                
  Well                                           3                5.9              5           13.2    0.128
  Moderately                                     18               35.3             20          52.6    
  Poorly                                         16               31.4             5           13.2    
  Unknown                                        14               27.5             8           21.1    
  Location of primary tumor                                                                            
  Cervical                                       1                2,0              4           10.5    0.159
  Upper thoracic                                 17               33.3             9           23.7    
  Middle thoracic                                26               51.0             16          42.1    
  Lower thoracic                                 7                13.7             9           23.7    
  Stage grouping (AJCC 2002)                                                                           
  Stage II                                       24               47.1             20          52.6    0.167
  Stage III                                      12               23.5             13          34.2    
  Stage IV                                       15               29.4             5           13.2    
  Response rate                                                                                        
  Complete and/or partial response               37               72.5             25          65.8    0.493
  Stable and/or progressive disease              14               27.5             13          34.2    
  Endoscopic biopsy at completion of treatment                                                         
  Negative                                       36               70.6             28          73.7    0.758
  Positive                                       15               29.4             10          26.3    
  Length of spinal irradiation when 40 Gy (cm)                                                         
  Mean                                           32.14                             18.78               0.000
  Standard deviation                             3.10                              3.57                

ECOG PS, Eastern Cooperative Oncology Group performance status; AJCC, American Joint Committee on Cancer; RECIST, Response Evaluation Criteria in Solid Tumors; ENI, elective nodal irradiation; CFI, conventional‐field irradiation.

John Wiley & Sons, Ltd

Treatment compliance {#cas13308-sec-0012}
--------------------

Four patients (3 in the ENI group and 1 in the CFI group) with stage IVB disease received two cycles of consolidation chemotherapy. The per‐protocol rate was 85.39% (76/89) for all patients, with 90.20% (46/51) in the ENI group and 78.95% (30/38) in the CFI group. Four patients received 38--40 Gy of radiation in the ENI group and 7 patients received 36--40 Gy of radiation in the CFI group. Sixteen patients declined to receive the second cycle of chemotherapy (10 in the ENI group and 6 in the CFI group). Five patients received a reduced dose of chemotherapy in the second cycle (2 in the ENI group and 3 in the CFI group).

Survival of all enrolled patients {#cas13308-sec-0013}
---------------------------------

Median follow‐up was 102.2 months (range 2.4--142.2) for the overall cohort: 123.1 months (range 3.17--142.2) in the ENI group and 91.2 months (Range 2.4--131.7) in the CFI group. There were 75 deaths among the 89 patients (84.27%) during the follow‐up period. Most (*n* = 56; 74.67%) died from recurrent cancer (28 in the ENI group and 28 in the CFI group). Nine patients died from intercurrent disease (3 in the ENI group and 6 in the CFI group) and 10 died from unknown causes (3 in ENI group and 7 in CFI group).

The median OS was 20.13 months (range, 2.4--131.7) in the ENI group and 17.30 months (range, 3.17--142.2) in the CFI group. The 5‐year and 10‐year OS were 33.8% *vs* 23.7% and 16.0% *vs* 13.2% for patients treated with ENI or CFI, respectively. There was no significant difference between the ENI group and the CFI group (hazard ratio \[HR\] = 0.87; 95% confidence interval \[CI\] 0.55--1.39; *P* = 0.561, Fig. [1](#cas13308-fig-0001){ref-type="fig"}a). The 5‐year and 10‐year disease‐specific OS were 43.0% *vs* 30.2% and 39.4% *vs* 16.8% for patients treated with ENI or CFI, respectively (HR = 1.21; 95% CI 0.74--1.97; *P* = 0.239, Fig. [1](#cas13308-fig-0001){ref-type="fig"}b). The 5‐year and 10‐year DFS were 33.1% *vs* 21.1% and 33.1% *vs* 14.1% for patients treated with ENI or with CFI, respectively (HR = 0.68; 95% CI 0.41--1.11; *P* = 0.120, Fig. [1](#cas13308-fig-0001){ref-type="fig"}c). The 5‐year and 10‐year LRFS were 43.8% *vs* 37.6% and 43.8% and 31.9% for patients treated with ENI or CFI, respectively (HR = 0.57; 95% CI 0.33--0.98; *P* = 0.039, Fig. [1](#cas13308-fig-0001){ref-type="fig"}d).

![Kaplan--Meier curves of overall survival (a), disease‐specific overall survival (b), disease‐free survival (c) and local recurrence‐free survival (d) for elective nodal irradiation (ENI) versus conventional‐field irradiation (CFI) (entire cohort).](CAS-108-1828-g001){#cas13308-fig-0001}

Survival of per‐protocol population {#cas13308-sec-0014}
-----------------------------------

There were 24 deaths among the 76 patients with per‐protocol treatment (46 in ENI group and 30 in CFI group). Table [2](#cas13308-tbl-0002){ref-type="table-wrap"} shows the characteristics of per‐protocol patients. The 5‐year OS (31.7% *vs* 22.9%) and 10‐year OS (13.6% *vs* 3.6%) were not significantly different between the ENI group and the CFI group (HR = 1.65, 95% CI 0.98--2.77; *P* = 0.056, Fig. [2](#cas13308-fig-0002){ref-type="fig"}a). The 5‐year and 10‐year disease‐specific OS were 47.0% *vs* 26.2% and 43.1% *vs* 10.5% for patients treated with ENI or with CFI, respectively (HR = 2.01, 95% CI 1.11--3.62; *P* = 0.019, Fig. [2](#cas13308-fig-0002){ref-type="fig"}b). The 5‐year and 10‐year DFS were 36.7% *vs* 15.3% and 36.7% *vs* 10.2% for patients treated with ENI or with CFI, respectively (HR = 1.78, 95% CI 1.02--3.13; *P* = 0.040, Fig. [2](#cas13308-fig-0002){ref-type="fig"}c). The 5‐year and 10‐year LRFS were 47.2% *vs* 25.8% and 47.2% *vs* 17.2% for patients treated with ENI or with CFI, respectively (HR = 2.09; 95% CI 1.12--3.93; *P* = 0.018, Fig. [2](#cas13308-fig-0002){ref-type="fig"}d).

###### 

Characteristics of per‐protocol patients

  Characteristics                     ENI (*N* = 46)   CFI (*N* = 30)   *P*‐value           
  ----------------------------------- ---------------- ---------------- ----------- ------- -------
  Age(years)                                                                                
  \<65                                25               54.3             14          46.7    0.561
  ≥65                                 21               45.7             16          53.3    
  Gender                                                                                    
  Male                                44               95.7             28          93.3    0.656
  Female                              2                4.3              2           6.7     
  ECOG PS                                                                                   
  0--1                                35               76.1             24          80.0    
  2                                   11               23.9             6           20.0    
  Tumor Length (cm)                                                                         
  \<5                                 6                13.0             5           16.7    0.586
  5--8                                25               54.3             19          63.3    
  \>8                                 15               32.7             6           20.0    
  Pathology                                                                                 
  Squamous carcinoma                  44               95.6             30          100.0   0.512
  Adenocarcinoma carcinoma            1                2.2              0                   
  Adenosquamous carcinoma             1                2.2              0                   
  Tumor differentiation                                                                     
  Well                                3                6.5              2           6.7     0.085
  Moderately                          16               34.8             18          60.0    
  Poorly                              14               30.4             4           13.3    
  Unknown                             13               28.3             6           20.0    
  Location of primary tumor                                                                 
  Cervical                            1                2.2              4           13.3    0.181
  Upper thoracic                      15               32.6             8           26.7    
  Middle thoracic                     24               52.2             12          40.0    
  Lower thoracic                      6                13.0             6           20.0    
  Stage grouping (AJCC 2002)                                                                
  Stage II                            22               47.8             16          53.3    0.281
  Stage III                           11               23.9             9           30.0    
  Stage IV                            13               28.3             5           16.7    
  Response rate                                                                             
  Complete and/or partial response    35               76.1             20          66.7    0.169
  Stable and/or progressive disease   11               23.9             10          33.3    

John Wiley & Sons, Ltd

![Kaplan--Meier curves of overall survival (a), disease‐specific overall survival (b), disease‐free survival (c), and local recurrence‐free survival (d) for elective nodal irradiation (ENI) versus conventional‐field irradiation (CFI) (per‐protocol population).](CAS-108-1828-g002){#cas13308-fig-0002}

Prognostic factors of per‐protocol population {#cas13308-sec-0015}
---------------------------------------------

As shown in Table [3](#cas13308-tbl-0003){ref-type="table-wrap"}, univariate analysis revealed the radiation field (HR 0.52, 95% CI 0.30--0.92; *P* = 0.025), tumor length (HR 1.60, 95% CI 1.01--2.53; *P* = 0.044) and clinical stage (HR 2.46, 95% CI 1.24--4.90; *P* = 0.010) as potentially influential factors for OS. The variables that were significantly associated with the LRFS were radiation field (HR 0.48, 95% CI 0.26--0.88; *P* = 0.018) and tumor length (HR 2.04, 95% CI 1.25--3.33; *P* = 0.005).

###### 

Univariate analysis (OS and LRFS)

  Factors                                                  OS     LRFS                                         
  -------------------------------------------------------- ------ ------------ ----------- ------ ------------ -----------
  Radiation field (ENI versus CFI)                         0.52   0.30--0.92   **0.025**   0.48   0.26--0.88   **0.018**
  Age (≤65 *vs* \>65)                                      0.95   0.53--1.69   0.862       0.88   0.48--1.62   0.682
  Gender (male versus female)                              0.65   0.16--2.67   0.545       0.35   0.05--2.56   0.301
  ECOG PS (0--1 *vs* 2)                                    0.76   0.38--1.54   0.450       0.82   0.38--1.78   0.624
  Tumor length (cm) (\<5 *vs* 5--8 *vs* \>8)               1.60   1.01--2.53   **0.044**   2.04   1.25--3.33   **0.005**
  Tumor differentiation (Well, moderately versus poorly)   1.06   0.51--2.20   0.884       1.25   0.60--2.60   0.552
  Clinical stage (II *vs* III *vs* IV)                     2.46   1.24--4.90   **0.010**   1.63   0.79--3.36   0.183

OS, overall survival; LRFS, local recurrence‐free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; ENI, elective nodal irradiation; CFI, conventional‐field irradiation; HR, hazard ratio; CI, confidence interval; bold: significant *P*‐values.

John Wiley & Sons, Ltd

The significant variables associated with OS or LRFS in the multivariable Cox model were: radiation field (OS: HR 0.39, 95% CI 0.21--0.72, *P* = 0.003; LRFS: HR 0.33, 95% CI 0.18--0.64, *P* = 0.001), tumor length (OS: HR 1.85, 95% CI 1.16--2.97, *P* = 0.010; LRFS: HR 2.63, 95% CI 1.55--4.47, *P* = 0.000) and clinical stage (OS: HR 2.57, 95% CI 1.28--5.14; *P* = 0.008) (Table [4](#cas13308-tbl-0004){ref-type="table-wrap"}).

###### 

Multivariate analysis (OS and LRFS)

  Factors                                      OS     LRFS                                     
  -------------------------------------------- ------ ------------ ------- ------ ------------ -------
  Radiation field (ENI versus CFI)             0.39   0.21--0.72   0.003   0.33   0.18--0.64   0.001
  Tumor length (cm) (\<5 *vs* 5--8 *vs* \>8)   1.85   1.16--2.97   0.010   2.63   1.55--4.47   0.000
  Clinical stage (II *vs* III *vs* IV)         2.57   1.28--5.14   0.008                       

OS, overall survival; LRFS, local recurrence‐free survival; ENI, elective nodal irradiation; CFI, conventional‐field irradiation; HR, hazard ratio; CI, confidence interval.

John Wiley & Sons, Ltd

Adverse effects {#cas13308-sec-0016}
---------------

For all 89 patients, no protocol‐related deaths were observed during treatment. Table [5](#cas13308-tbl-0005){ref-type="table-wrap"} shows the most frequently acute toxicities. In the present study, 13 (31.4%) of 51 patients in the ENI group had severe (grade ≥3) radiation esophagitis *vs* 5 (13.2%) of 38 patients in the CFI group (*P* = 0.035). Other severe acute toxicities were similar between the ENI group and the CFI group.

###### 

Acute Toxicities

  Acute toxicities        ENI group (*N* = 51)   CFI group (*N* = 38)                
  ----------------------- ---------------------- ---------------------- ------------ -----------
  Haematological                                                                     
  Leucopenia              36 (70.6%)             10 (19.6%)             28 (73.7%)   7 (18.4%)
  Neutropenia             34 (66.7%)             17 (27.5%)             24 (63.2%)   9 (29.0%)
  Thrombocytopenia        11 (21.6%)             4 (7.8%)               8 (21.1%)    4 (10.5%)
  Anaemia                 15 (29.4%)             2 (3.9%)               11 (28.9%)   2 (5.3%)
  Non‐haematological                                                                 
  Nausea                  16 (31.4%)             3 (5.9%)               11 (28.9%)   3 (7.9%)
  Vomiting                8 (15.7%)              4 (7.8%)               5 (13.2%)    2 (5.3%)
  Diarrhea                5 (9.8%)               2 (3.9%)               4 (10.5%)    3 (7.9%)
  Fatigue                 16 (31.4%)             9 (17.6%)              12 (31.6%)   8 (21.1%)
  Renal insufficiency     2 (3.9%)               0                      1 (2.6%)     0
  Cardiac disorders       1 (2.0%)               0                      1 (2.6%)     0
  Radiation esophagitis   33 (64.7%)             16 (31.4%)             25 (65.8%)   5 (13.2%)

ENI, elective nodal irradiation; CFI, conventional‐field irradiation.

John Wiley & Sons, Ltd

At the end of follow up, 65 patients (37 in the ENI group and 28 in the CFI group) were eligible for evaluating the late toxicities. The late toxicities were similar between the ENI group and the CFI group (*P* \> 0.05). No radioactive myelitis was seen in either group. There were 4 late toxicity‐related deaths, with 2 patients in each group. The ENI did not exacerbate the acute and late toxicities associated with chemotherapy in patients with esophageal cancer.

Patterns of failure and salvage treatment {#cas13308-sec-0017}
-----------------------------------------

For all enrolled patients, 63 patients experienced treatment failure, with local--regional recurrences only in 38 patients (60.3%), distant metastasis only in 20 patients (31.7%), and both local--regional and distant metastasis in 5 patients (8.0%). For the per‐protocol population, 31 patients experienced treatment failure, which was local‐regional only in 17 patients (54.8%), distant only in 10 patients (32.3%), and both local‐regional and distant in 4 patients (12.9%). A total of 13 patients with loco‐regional recurrence without distant metastasis received salvage therapy including surgery (2 in the ENI group and 4 in the CFI group) or radiotherapy (4 in the ENI group and 3 in the CFI group). There were no deaths related to salvage treatment.

Discussion {#cas13308-sec-0018}
==========

The CFI has been used as a standard treatment for esophageal patients with reduced incidence of radiation toxicities. However, approximately 85% of patients failed locoregionally inside the radiation fields. The local‐regional failure rate was decreased in RTOG 85‐01 (44.3%), which used ENI rather than the standard‐dose arm in 94‐05 (55%), which omitted ENI.[8](#cas13308-bib-0008){ref-type="ref"} Furthermore, it has been reported that 71% of lymph nodes classified as tumor‐free by routine histopathology showed lymphatic micro‐metastases with immunohistochemistry.[16](#cas13308-bib-0016){ref-type="ref"} ENI is currently a standard treatment for esophageal cancer patients in Japan.

To date, there are no prospective randomized trials to compare the efficacy between ENI and CFI in esophageal cancer. However, several retrospective studies have demonstrated that ENI is effective for preventing loco‐regional failure with manageable toxicities.[17](#cas13308-bib-0017){ref-type="ref"}, [18](#cas13308-bib-0018){ref-type="ref"}, [19](#cas13308-bib-0019){ref-type="ref"} In a retrospective study, ENI improved survival compared with a normal radiation field.[18](#cas13308-bib-0018){ref-type="ref"} Yamashita *et al*.[19](#cas13308-bib-0019){ref-type="ref"} report that ENI including the gross tumor volume and elective lymph nodes significantly decreased the elective nodal failure for patients with thoracic esophageal squamous cell cancer.

To our knowledge, there has been no long‐term follow‐up study of patients with esophageal cancer receiving ENI in combination with concurrent chemotherapy. Our results showed that no significant differences between ENI and CFI groups were found for OS, disease‐specific OS and DFS. However, the ENI group had a significantly higher LRFS than the CFI group. For the per‐protocol population, the ENI group significantly improved in regards to 5‐year and 10‐year disease‐specific OS, DFS and LRFS compared with the CFI group. These results suggest that ENI improved both disease‐specific OS and local‐regional control in patients with inoperable esophageal cancer receiving per‐protocol treatment.

The superiority of the ENI radiation with chemotherapy cannot be attributed to underperformance in the CFI group. The median survival of 17.30 months and 5‐year OS were 29.3% for the CNI group, which was similar to that observed in RTOG 85‐01.[6](#cas13308-bib-0006){ref-type="ref"}

A radiation dose of 60 Gy was administered in the present study. In our systemic review and pooled analysis, ≥60 Gy concurrent chemoradiotherapy improved the response rate, local‐regional control, distant failure and OS without a significant increase in radiation‐related toxicities.[20](#cas13308-bib-0020){ref-type="ref"} A recent population‐based propensity‐score‐matched analysis also showed that a high dose (≥60 Gy) may lead to better survival for non‐operated localized esophageal squamous cell cancer patients undergoing concurrent chemoradiotherapy.[21](#cas13308-bib-0021){ref-type="ref"} It is reasonable to believe that delivering a prescribed dose of 60 Gy at 2.0 Gy/fraction is an appropriate radiation regimen in the definitive concurrent chemoradiotherapy for Chinese patients with esophageal cancer.[22](#cas13308-bib-0022){ref-type="ref"}

The acute and late toxicities were relatively high in the ENI group and presumably caused by the extended radiation field. A wider radiation field may increase the esophagitis. In our study, ENI was associated with a higher rate of ≥ grade 3 radiation‐induced esophagitis compared with CFI. Other radiation‐related toxicities and treatment compliance were similar between the two groups. Although the incidence was relatively high, acute toxicity was manageable with sufficient support. The ENI could be safely added to concurrent chemotherapy. Grade ≥2 late toxicities were observed in 38.5% of patients, mainly with radiation pneumonitis (21.5%) and esophageal stenosis (24.6%), which was comparable to that reported by previous studies.[23](#cas13308-bib-0023){ref-type="ref"}, [24](#cas13308-bib-0024){ref-type="ref"} In addition, in the present study, 5 patients developed second malignancies, 2 patients had lung cancer, 2 patients had gastric cancer and 1 patient had a laryngocarcinoma. Two patients received surgical treatment.

For loco‐regional recurrence patients, salvage treatment including surgery or radiotherapy is a possible therapeutic option. It has been reported that 13%--30% of patients undergo salvage surgery after definitive CRT.[25](#cas13308-bib-0025){ref-type="ref"}, [26](#cas13308-bib-0026){ref-type="ref"} Although the postoperative mortality remains high (10%--33%), some patients achieve long‐term survival with a 5‐year survival rate of 25%--35%.[27](#cas13308-bib-0027){ref-type="ref"}, [28](#cas13308-bib-0028){ref-type="ref"} The patients with pretreatment T1--2 tumors and those with relapse after CR are eligible for salvage esophagectomy.[29](#cas13308-bib-0029){ref-type="ref"} In the present study, 13 patients underwent salvage treatment and there were no deaths related to salvage treatment. The optimal timing and procedure of salvage therapy is evaluated in JCOG 0909, a phase II trial of CRT for resectable esophageal squamous cell cancer followed by salvage surgery for residual or recurrent disease. Salvage therapeutic strategy after chemoradiotherapy should be considered at the time that treatment is initiated.

There are some limitations of our study. First, this was a nonrandomized, retrospective study and might suffer from potential selection bias. The second limitation was the relatively small sample size in our study.

Our study showed that ENI with concurrent TP chemotherapy improves both loco‐regional control and disease‐specific survival of patients with inoperable esophageal cancer receiving per‐protocol treatment, without increasing toxicity. Further prospective and randomized trials would be required to confirm the role of ENI in the treatment of patients with inoperable esophageal cancer.
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